Clinical Trials Logo

Advanced Colorectal Carcinoma clinical trials

View clinical trials related to Advanced Colorectal Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04645797 Completed - Clinical trials for Advanced Colorectal Carcinoma

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Start date: January 20, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

NCT ID: NCT01277406 Completed - Clinical trials for Advanced Colorectal Carcinoma

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma

SHORE
Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.

NCT ID: NCT01208194 Completed - Clinical trials for Advanced Colorectal Carcinoma

Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma

IMPACT
Start date: June 2010
Phase: Phase 2
Study type: Interventional

This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after first-line standard chemotherapy regimens.

NCT ID: NCT00499850 Completed - Clinical trials for Advanced Colorectal Carcinoma

Phase I FOLFOX Combination

Start date: August 2005
Phase: Phase 1
Study type: Interventional

A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.